Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 12 | 2021 | 1536 | 1.760 |
Why?
|
| Melanoma | 5 | 2020 | 335 | 1.410 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2021 | 33 | 1.360 |
Why?
|
| Skin Neoplasms | 5 | 2020 | 375 | 1.360 |
Why?
|
| Mastectomy, Segmental | 8 | 2021 | 64 | 1.290 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2021 | 62 | 1.160 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 334 | 1.160 |
Why?
|
| Yttrium Radioisotopes | 2 | 2018 | 4 | 1.140 |
Why?
|
| Embolization, Therapeutic | 2 | 2018 | 150 | 0.970 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 124 | 0.740 |
Why?
|
| Workplace | 1 | 2020 | 75 | 0.700 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2016 | 446 | 0.700 |
Why?
|
| Burnout, Professional | 1 | 2020 | 64 | 0.680 |
Why?
|
| Intraoperative Care | 3 | 2016 | 91 | 0.660 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 135 | 0.660 |
Why?
|
| Uveal Neoplasms | 1 | 2018 | 16 | 0.630 |
Why?
|
| Internship and Residency | 2 | 2022 | 596 | 0.620 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 214 | 0.620 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.610 |
Why?
|
| Mastectomy | 2 | 2021 | 57 | 0.590 |
Why?
|
| Lymph Node Excision | 3 | 2017 | 91 | 0.570 |
Why?
|
| Physicians | 1 | 2020 | 324 | 0.560 |
Why?
|
| Prognosis | 9 | 2021 | 2093 | 0.560 |
Why?
|
| Health Promotion | 1 | 2020 | 407 | 0.550 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 298 | 0.540 |
Why?
|
| Middle Aged | 23 | 2021 | 21147 | 0.510 |
Why?
|
| Aged | 21 | 2021 | 14862 | 0.510 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 4848 | 0.500 |
Why?
|
| Retrospective Studies | 16 | 2021 | 7277 | 0.500 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 498 | 0.500 |
Why?
|
| Radiotherapy | 2 | 2016 | 86 | 0.500 |
Why?
|
| Length of Stay | 5 | 2017 | 780 | 0.480 |
Why?
|
| Carcinoma | 1 | 2015 | 215 | 0.450 |
Why?
|
| Brachytherapy | 1 | 2013 | 79 | 0.440 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 561 | 0.430 |
Why?
|
| Female | 25 | 2021 | 38074 | 0.430 |
Why?
|
| Electrocoagulation | 1 | 2012 | 35 | 0.410 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 168 | 0.400 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 12 | 0.400 |
Why?
|
| Anus Neoplasms | 1 | 2012 | 37 | 0.400 |
Why?
|
| Mammaplasty | 1 | 2012 | 41 | 0.390 |
Why?
|
| Sarcoma | 1 | 2012 | 70 | 0.390 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 83 | 0.390 |
Why?
|
| Humans | 28 | 2022 | 68618 | 0.370 |
Why?
|
| Hospital Mortality | 1 | 2012 | 384 | 0.360 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 299 | 0.350 |
Why?
|
| Postoperative Complications | 3 | 2017 | 1615 | 0.330 |
Why?
|
| Age Factors | 4 | 2021 | 1864 | 0.330 |
Why?
|
| Adult | 14 | 2021 | 21403 | 0.320 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 800 | 0.280 |
Why?
|
| Perception | 2 | 2020 | 189 | 0.280 |
Why?
|
| Robotic Surgical Procedures | 2 | 2017 | 49 | 0.260 |
Why?
|
| Survival Rate | 3 | 2018 | 1056 | 0.250 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 67 | 0.230 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 33 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 475 | 0.220 |
Why?
|
| Male | 13 | 2021 | 37321 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 274 | 0.200 |
Why?
|
| Perioperative Period | 1 | 2021 | 24 | 0.200 |
Why?
|
| Young Adult | 4 | 2021 | 5717 | 0.200 |
Why?
|
| Clinical Clerkship | 1 | 2022 | 63 | 0.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2020 | 53 | 0.190 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 95 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2018 | 7029 | 0.190 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 117 | 0.190 |
Why?
|
| Waste Management | 1 | 2020 | 11 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3259 | 0.180 |
Why?
|
| Mitosis | 1 | 2020 | 76 | 0.180 |
Why?
|
| Students, Medical | 1 | 2022 | 210 | 0.180 |
Why?
|
| Operative Time | 3 | 2017 | 45 | 0.170 |
Why?
|
| General Surgery | 1 | 2020 | 95 | 0.170 |
Why?
|
| Reoperation | 1 | 2021 | 467 | 0.170 |
Why?
|
| Carcinoma, Lobular | 2 | 2016 | 20 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 378 | 0.160 |
Why?
|
| Time Factors | 4 | 2015 | 4655 | 0.160 |
Why?
|
| Anxiety | 1 | 2021 | 422 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 125 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 142 | 0.150 |
Why?
|
| Glycation End Products, Advanced | 1 | 2018 | 125 | 0.150 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 425 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2017 | 258 | 0.150 |
Why?
|
| Radiotherapy Dosage | 2 | 2016 | 125 | 0.140 |
Why?
|
| Skin | 1 | 2020 | 451 | 0.140 |
Why?
|
| Esophagectomy | 1 | 2017 | 26 | 0.140 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2016 | 18 | 0.140 |
Why?
|
| DNA Polymerase II | 1 | 2016 | 5 | 0.140 |
Why?
|
| F-Box Proteins | 1 | 2016 | 14 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2020 | 413 | 0.140 |
Why?
|
| Life Style | 1 | 2018 | 338 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 792 | 0.140 |
Why?
|
| SEER Program | 2 | 2020 | 153 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 150 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 89 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2800 | 0.130 |
Why?
|
| Patient Selection | 2 | 2016 | 592 | 0.130 |
Why?
|
| Axilla | 1 | 2015 | 36 | 0.130 |
Why?
|
| Choristoma | 1 | 2015 | 20 | 0.130 |
Why?
|
| Rose Bengal | 1 | 2014 | 3 | 0.120 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2014 | 2 | 0.120 |
Why?
|
| Disease Progression | 1 | 2018 | 1038 | 0.120 |
Why?
|
| BCG Vaccine | 1 | 2014 | 12 | 0.120 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 25 | 0.120 |
Why?
|
| United States | 4 | 2022 | 7367 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 1 | 2014 | 63 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2016 | 714 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 230 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 57 | 0.120 |
Why?
|
| Breast | 1 | 2015 | 137 | 0.120 |
Why?
|
| Patient Readmission | 2 | 2017 | 267 | 0.120 |
Why?
|
| Iridium Radioisotopes | 1 | 2013 | 11 | 0.120 |
Why?
|
| Interleukin-2 | 1 | 2014 | 133 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2014 | 87 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2016 | 237 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1046 | 0.110 |
Why?
|
| Quality of Life | 1 | 2021 | 1515 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 62 | 0.110 |
Why?
|
| Adolescent | 4 | 2020 | 8912 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 332 | 0.110 |
Why?
|
| Inguinal Canal | 1 | 2012 | 5 | 0.110 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2012 | 20 | 0.100 |
Why?
|
| Genetic Therapy | 1 | 2014 | 291 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2012 | 58 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 756 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 242 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 504 | 0.100 |
Why?
|
| Colectomy | 1 | 2012 | 64 | 0.100 |
Why?
|
| Lidocaine | 1 | 2012 | 36 | 0.100 |
Why?
|
| Camping | 1 | 2011 | 6 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 85 | 0.100 |
Why?
|
| Epinephrine | 1 | 2012 | 103 | 0.100 |
Why?
|
| Fires | 1 | 2011 | 21 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 306 | 0.100 |
Why?
|
| Bronchodilator Agents | 1 | 2012 | 43 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2016 | 2358 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 629 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2015 | 3705 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 546 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2012 | 120 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 369 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 23 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2010 | 21 | 0.090 |
Why?
|
| Burns | 1 | 2011 | 83 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2010 | 40 | 0.090 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2010 | 29 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2012 | 880 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 53 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 1076 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2011 | 275 | 0.080 |
Why?
|
| Sentinel Lymph Node | 2 | 2020 | 4 | 0.080 |
Why?
|
| Pediatrics | 1 | 2011 | 341 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 1266 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 468 | 0.070 |
Why?
|
| Risk Factors | 2 | 2018 | 5731 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2017 | 132 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 951 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 2223 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 2007 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2022 | 157 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2022 | 254 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 536 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 111 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2018 | 62 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 11 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 18 | 0.040 |
Why?
|
| Learning Curve | 1 | 2016 | 20 | 0.040 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2016 | 7 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 112 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 79 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2018 | 146 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 332 | 0.030 |
Why?
|
| Florida | 1 | 2016 | 221 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 81 | 0.030 |
Why?
|
| Medical Errors | 1 | 2016 | 80 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 38 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 110 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 125 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 267 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 160 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 349 | 0.030 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2015 | 2 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 186 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 50 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2015 | 238 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 253 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1851 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 867 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 733 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1426 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1664 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 1603 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1054 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 117 | 0.020 |
Why?
|
| Mutation | 1 | 2016 | 1213 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 21 | 0.020 |
Why?
|
| Mitomycin | 1 | 2010 | 27 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 26 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 58 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 940 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 2689 | 0.020 |
Why?
|
| Hospitalization | 1 | 2011 | 978 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 2891 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 3187 | 0.020 |
Why?
|
| Child | 1 | 2011 | 6405 | 0.010 |
Why?
|